Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states.
With interventional cardiology, interventional oncology and the treatment of peripheral artery disease being the three pillars of Terumo Europe Interventional Systems, until now, peripheral artery disease treatment and interventional oncology were managed as one entity. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states.
This new organisation will reinforce the commitment of Terumo Europe towards oncology patients and healthcare professionals by bringing to the market new products already in development, and their clinical data through a comprehensive clinical trial programme, the release adds.
Peter Coenen, president of Terumo Europe Interventional Systems commented: “We have an exciting portfolio of in-house products coming up and we plan significant clinical investments. We believe that specialised teams will increase Terumo Europe’s leadership in this field. It will strengthen our relationship within the medical community.”
